Aug 31, 2007 by Brian Orelli, PhDA Stem-Cell PrimerPublic funding from states could help the companies doing the research.
Aug 30, 2007 by Brian Orelli, PhDForget What Your Drug Was Approved ForBaxter stages a new trial for an old drug.
Aug 30, 2007 by Brian Orelli, PhDMerck Tries to Stop the FlushingThe FDA will review its new cholesterol drug.
Aug 29, 2007 by Brian Orelli, PhDInverness Trades Stock for RevenueMatritech becomes the latest of Inverness' acquisitions.
Aug 29, 2007 by Brian Orelli, PhDPrevention for Your PortfolioHow to benefit from increased spending on preventative medicine.
Aug 28, 2007 by Brian Orelli, PhDA Combination to Clear Your HeadMerck and Schering-Plough get together again.
Aug 28, 2007 by Brian Orelli, PhDFDA Makes Cows HappyOmrix's human-derived thrombin will replace a version made from cattle.
Aug 27, 2007 by Brian Orelli, PhDFDA's Burning RegulationsNew rules about sunscreen could mean a new market leader.
Aug 27, 2007 by Brian Orelli, PhDOnyx: Old News Is Good NewsNexavar successfully treats liver cancer -- just like it did six months ago.
Aug 24, 2007 by Brian Orelli, PhDKids, Take Your PsychoactivesJ&J gains pediatric approval of its antipsychosic drug.
Aug 24, 2007 by Brian Orelli, PhDTake Your Medicine; Earn Your ProfitsPersonalized medicine offers investment ideas.
Aug 23, 2007 by Brian Orelli, PhDCan't Stop the Bleeding From a Paper CutZymoGenetics' rThrombin product is delayed.
Aug 22, 2007 by Brian Orelli, PhDRegulating the Drug PushersThe FDA might get a little tougher on drug ads.
Aug 21, 2007 by Brian Orelli, PhDPushing PillsSpending on drug lobbying increases. What do companies have to show for it?
Aug 21, 2007 by Brian Orelli, PhDSweet Phase 3 DataNovo Nordisk's newest diabetes drug looks promising.
Aug 20, 2007 by Brian Orelli, PhDContracts That Are for the BirdsBaxter and GlaxoSmithKline get bird flu vaccine contracts from the U.K.
